Targeting Epigenetic Regulators with HDAC and BET Inhibitors to Modulate Muscle Wasting

Area of Science:

• Muscle physiology and epigenetics
• Molecular mechanisms of muscle wasting
• Therapeutic potential of epigenetic modulation

Background:

• Epigenetic alterations drive transcriptional changes in muscle wasting conditions.
• Histone deacetylase (HDAC) inhibitors are studied in muscular dystrophies, but their role in cancer cachexia and sarcopenia is less explored.
• Bromodomain and extraterminal (BET) inhibitors are emerging epigenetic drugs with potential beyond cancer.

Purpose of the Study:

• To explore the role of epigenetic inhibitors, specifically targeting HDACs and BET proteins, in combating muscle atrophy.
• To investigate the potential of these inhibitors in conditions like cancer cachexia and sarcopenia.
• To assess whether targeting HDACs and BET proteins can reverse the catabolic state in muscle wasting disorders.

Main Methods:

• Review of preliminary in vitro and preclinical data on HDACs and BET proteins in muscle atrophy.
• Analysis of the contribution of these proteins to skeletal muscle mass maintenance and metabolism.
• Evaluation of the therapeutic potential of epigenetic drugs targeting HDACs and BET pathways.

Main Results:

• Preliminary data suggest HDACs and BET proteins are implicated in the pathogenesis of cancer cachexia and sarcopenia.
• These proteins modulate key processes in skeletal muscle mass maintenance and metabolism.
• Epigenetic drugs targeting HDACs and BET proteins demonstrate potential in preclinical models.

Conclusions:

• HDACs and BET proteins are significant contributors to muscle wasting in cancer cachexia and sarcopenia.
• Epigenetic drugs targeting these proteins represent a promising therapeutic strategy for muscle atrophy.
• Further preclinical investigation is essential to elucidate molecular mechanisms and confirm therapeutic efficacy.